GLP-1 & SGLT2i for CV/Renal Benefits

GLP-1 & SGLT2i for CV/Renal Benefits

Master cardiovascular and renal protection strategies in diabetes with free flashcards and evidence-based practice recommendations. This lesson covers GLP-1 receptor agonist mechanisms, SGLT2 inhibitor benefits, patient selection criteria, and landmark trial data—essential concepts for NAPLEX success and optimal patient care.

---

Welcome to CV/Renal Benefits of Newer Diabetes Agents 💊

The landscape of diabetes management has transformed dramatically with the discovery that GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) offer benefits far beyond glucose control. These agents reduce cardiovascular events, slow chronic kidney disease progression, and improve mortality outcomes in high-risk populations.

For NAPLEX, you must know:

• Which patients benefit most from each drug class 🎯
• Specific cardiovascular and renal outcome data 📊
• How to integrate these agents into comprehensive diabetes care 🔄
• Key contraindications and monitoring parameters ⚠️

This isn't just about A1C reduction anymore—it's about organ protection and extending lives.

---

Core Concept 1: GLP-1 Receptor Agonists - Mechanisms Beyond Glucose 🧬

How GLP-1 RAs Work

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that:

• Enhances glucose-dependent insulin secretion 📈
• Suppresses glucagon release when glucose is elevated 📉
• Slows gastric emptying 🐌
• Reduces appetite through central nervous system effects 🧠

Cardiovascular Protective Mechanisms

Beyond glycemic control, GLP-1 RAs provide CV benefits through:

Landmark GLP-1 RA Cardiovascular Outcome Trials

🔬 Key Trials to Memorize:

LEADER (Liraglutide):

• 13% reduction in 3-point MACE (CV death, non-fatal MI, non-fatal stroke)
• 22% reduction in CV death
• 22% reduction in all-cause mortality
• Population: Type 2 DM + established CVD or CV risk factors

SUSTAIN-6 (Semaglutide SC):

• 26% reduction in 3-point MACE
• Significant ↓ non-fatal stroke
• Notable: Also showed renal benefits (↓ new/worsening nephropathy)

REWIND (Dulaglutide):

• 12% reduction in 3-point MACE
• Important: Majority (68.5%) had NO prior CVD—demonstrates primary prevention benefit

AMPLITUDE-O (Efpeglenatide):

• 27% reduction in 4-point MACE
• Significant mortality benefit

💡 NAPLEX Pearl: Semaglutide and dulaglutide are first-line recommendations for patients with T2DM and established ASCVD per ADA/AACE guidelines.

Renal Benefits of GLP-1 RAs

While not as robust as SGLT2i for kidney protection, GLP-1 RAs show:

• ↓ Albuminuria progression (20-30% reduction)
• ↓ Rate of eGFR decline
• ↓ Composite renal endpoints in CV outcome trials
• Mechanism: Likely indirect through BP reduction, weight loss, glycemic control, and anti-inflammatory effects

⚠️ Important Note: GLP-1 RAs are NOT contraindicated in chronic kidney disease and can be used at any eGFR level (though dose adjustments vary by agent).

---

Core Concept 2: SGLT2 Inhibitors - Renal and Cardiac Game-Changers 🎯

Mechanism of Action

Sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule reabsorbs ~90% of filtered glucose. Blocking SGLT2:

• Causes glucosuria (50-80 g glucose/day excreted) 🚽
• Lowers A1C by 0.5-1% (glucose-dependent effect)
• Promotes osmotic diuresis → ↓ volume (1-2 kg weight loss initially)
• Results in caloric loss → additional 2-3 kg weight reduction

Cardiovascular Benefits: The Heart Failure Revolution 💓

SGLT2i are now FIRST-LINE therapy for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status!

🧠 Mnemonic for SGLT2i HF Trials: "DAPPER EMPEROR"

• DAPagliflozin (DAPA-HF, DELIVER)
• EmPAGliflozin (EMPEROR-Reduced, EMPEROR-Preserved)
• Both ERase heart failure hospitalizations

Proposed Mechanisms for Cardiac Benefits

The exact mechanism remains debated, but likely multifactorial:

┌─────────────────────────────────────────────┐
│   SGLT2i CARDIOPROTECTIVE PATHWAYS         │
├─────────────────────────────────────────────┤
│                                             │
│  💧 Volume Reduction (↓ preload)           │
│         ↓                                   │
│  🩺 BP Reduction (2-4 mmHg systolic)       │
│         ↓                                   │
│  ⚡ Improved Myocardial Energetics          │
│    (↑ ketone utilization as fuel)          │
│         ↓                                   │
│  🔬 Reduced Inflammation & Fibrosis         │
│         ↓                                   │
│  ⚖️ Favorable Metabolic Effects             │
│    (↓ uric acid, ↑ hematocrit)             │
│         ↓                                   │
│  🫀 REDUCED HF HOSPITALIZATIONS             │
│                                             │
└─────────────────────────────────────────────┘

Renal Protection: The Primary Benefit ⚕️

SGLT2i provide profound renal protection through multiple mechanisms:

Hemodynamic Effects:

1. Tubuloglomerular feedback restoration 🔄

   • ↑ Distal sodium delivery → afferent arteriole vasoconstriction
   • ↓ Intraglomerular pressure (↓ hyperfiltration)
   • Protects podocytes from mechanical stress

2. Reduced kidney workload

   • ↓ Sodium reabsorption → ↓ oxygen consumption
   • Improved medullary oxygenation

Landmark Renal Outcome Trials:

CREDENCE (Canagliflozin):

• Population: T2DM + CKD (eGFR 30-90, albuminuria)
• 30% reduction in primary composite: ESKD, doubling of SCr, renal/CV death
• 34% reduction in ESKD alone
• Trial stopped early due to overwhelming efficacy! 🎊

DAPA-CKD (Dapagliflozin):

• Population: CKD (eGFR 25-75) with/without diabetes
• 39% reduction in renal composite (eGFR decline ≥50%, ESKD, renal/CV death)
• 31% reduction in all-cause mortality
• Benefit seen regardless of diabetes status!

EMPA-KIDNEY (Empagliflozin):

• Population: Broad CKD (eGFR 20-45 or 45-90 with albuminuria)
• 28% reduction in renal disease progression or CV death
• Consistent benefit across all subgroups

💡 Clinical Pearl: SGLT2i slow eGFR decline long-term despite causing an initial acute dip in eGFR (5-10% in first 2-4 weeks—this is expected and hemodynamic, not nephrotoxic!).

⚠️ NAPLEX Alert: Do NOT discontinue SGLT2i due to initial eGFR dip unless >30% decline or other concerning factors (AKI, volume depletion).

---

Core Concept 3: Patient Selection - Who Benefits Most? 🎯

ADA/AACE Guideline Recommendations (2024)

📋 Indication-Based Approach (independent of A1C or metformin use):

🤔 GLP-1 RA vs. SGLT2i: How to Choose?

Both can be used together! But when choosing one:

Absolute Contraindications ⚠️

GLP-1 RA:

• Personal/family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of severe GI disease (gastroparesis, IBD)
• Pregnancy (Category C—discontinue if planning pregnancy)

SGLT2i:

• Type 1 diabetes (relative—higher DKA risk; use only with extreme caution and FDA-approved indications like dapagliflozin for HF)
• History of diabetic ketoacidosis (DKA)
• Severe recurrent UTIs or genital infections (relative)
• eGFR <20 (canagliflozin <30)—though recent data suggests safety/benefit down to eGFR 20

💡 NAPLEX Tip: Neither class causes hypoglycemia as monotherapy (glucose-dependent mechanisms). However, when combined with insulin or sulfonylureas, adjust those agents to prevent hypo.

---

Core Concept 4: Adverse Effects & Safety Monitoring 🔍

GLP-1 RA Adverse Effects

Most Common (>10% incidence):

• Nausea (20-40%, usually transient) 🤢
• Vomiting (10-20%)
• Diarrhea (10-20%)
• Constipation (less common but possible)

💊 Mitigation Strategies:

• Start at lowest dose, titrate slowly (every 4 weeks minimum)
• Take with food initially
• Eat smaller, more frequent meals
• Avoid high-fat meals (worsen GI symptoms)
• Symptoms typically improve after 4-8 weeks

Serious but Rare:

• Pancreatitis (<0.5%)—discontinue if suspected
• Gallbladder disease (↑ risk with rapid weight loss)
• Retinopathy worsening (seen in SUSTAIN-6 with rapid A1C reduction)
• Medullary thyroid carcinoma (black box warning—rodent data, no human cases confirmed)

SGLT2i Adverse Effects

Common:

• Genital mycotic infections (10-15% women, 3-5% men) 🍄

  • Treat with topical antifungals
  • Usually do NOT require discontinuation
  • Prevention: good hygiene, proper drying

• UTIs (5-10%)

  • Similar to general population
  • Treat per standard guidelines

• Volume depletion/hypotension (2-5%)

  • Higher risk: elderly, loop diuretics, low BP baseline
  • Monitor orthostatic symptoms
  • May need diuretic dose reduction

Serious (Rare):

Diabetic Ketoacidosis (DKA) - "Euglycemic DKA" 🚨

• Occurs in ~0.1% (rare but serious)
• Called "euglycemic" because glucose may be <250 mg/dL
• Risk factors: T1DM, acute illness, surgery, low carb diet, insulin reduction, alcohol

Fournier's Gangrene (Necrotizing Fasciitis of Perineum) 💀

• Extremely rare (~0.001%) but life-threatening
• FDA black box warning (2018)
• Symptoms: Genital/perineal pain, tenderness, erythema, fever
• Action: Discontinue immediately, urgent surgical evaluation

Bone Fractures & Amputation (Canagliflozin)

• Increased fracture risk seen in CANVAS trial
• ↑ Lower limb amputation risk (primarily toes)
• Mechanism unclear—possibly related to falls from hypotension or direct bone effects
• Clinical action: Avoid canagliflozin if high fracture risk or PAD with amputation history

Monitoring Parameters 📊

---

Clinical Examples with Detailed Explanations 📚

Example 1: Post-MI Patient with Diabetes

Case: 62-year-old male, 3 months post-STEMI with stent placement. PMH: T2DM (A1C 8.2%), hypertension, dyslipidemia. Current meds: Metformin 1000 mg BID, atorvastatin 80 mg daily, aspirin 81 mg daily, clopidogrel 75 mg daily, metoprolol succinate 50 mg daily, lisinopril 20 mg daily. Patient asks about newer diabetes medications he saw advertised.

❓ Question: Which diabetes medication class should be prioritized and why?

✅ Answer: GLP-1 RA with proven CV benefit (semaglutide, liraglutide, or dulaglutide)

📖 Explanation:

• Patient has established ASCVD (recent MI)—highest-priority indication
• GLP-1 RAs showed CV death reduction in LEADER (liraglutide) and SUSTAIN-6 (semaglutide)
• These agents reduce recurrent MACE events
• A1C 8.2% indicates need for additional glucose-lowering
• Would provide cardioprotection + glycemic control + modest weight loss
• SGLT2i would be alternative/complementary choice, especially if HF develops

💊 Specific Recommendation:

• Start semaglutide 0.25 mg SC weekly × 4 weeks → increase to 0.5 mg weekly (maintenance)
• Counsel on GI effects (nausea common initially, improves with time)
• Continue metformin (synergistic, no interaction)
• Monitor A1C in 3 months (expect 1-1.5% reduction)
• Consider adding SGLT2i if A1C still not at goal or if HF/CKD develops

---

Example 2: Heart Failure Patient Without Diabetes

Case: 58-year-old female with HFrEF (EF 35%), NYHA Class II symptoms. No diabetes (A1C 5.6%, fasting glucose 98 mg/dL). Currently on sacubitril/valsartan 97/103 mg BID, carvedilol 25 mg BID, spironolactone 25 mg daily, furosemide 40 mg daily. eGFR 55 mL/min/1.73m². Cardiologist requests medication therapy management consultation for "optimal GDMT."

❓ Question: Should an SGLT2 inhibitor be added despite absence of diabetes?

✅ Answer: YES—SGLT2i is indicated and first-line for HFrEF regardless of diabetes status!

📖 Explanation:

• DAPA-HF and EMPEROR-Reduced trials included patients with and without diabetes
• 26% relative risk reduction in CV death or HF hospitalization seen in BOTH groups
• SGLT2i are now Class I recommendation (Benefit >>> Risk) in ACC/AHA/HFSA HF guidelines
• Should be considered one of the "four pillars" of HFrEF therapy:
  1. ACE-I/ARB/ARNI (✅ has sacubitril/valsartan)
  2. Beta-blocker (✅ has carvedilol)
  3. MRA (✅ has spironolactone)
  4. SGLT2i (❌ MISSING—should add!)

💊 Specific Recommendation:

• Add dapagliflozin 10 mg PO daily (FDA-approved for HFrEF with/without DM)
• Alternative: empagliflozin 10 mg PO daily
• eGFR 55 is adequate (approved down to eGFR >25 for dapagliflozin in HF)
• Counsel:
  • May cause initial 1-2 kg weight loss (fluid)
  • Monitor for orthostatic symptoms (already on multiple BP meds)
  • Consider reducing furosemide if volume depleted
  • Genital hygiene to prevent mycotic infections
• Monitor: eGFR in 2-4 weeks (expect small dip), BP, volume status

💡 NAPLEX Pearl: This scenario tests whether you know SGLT2i benefit extends beyond diabetes—this is HIGH-YIELD!

---

Example 3: CKD Patient with Multiple Comorbidities

Case: 67-year-old male with T2DM (A1C 8.5%), stage 3b CKD (eGFR 38 mL/min/1.73m², urine albumin-to-creatinine ratio 450 mg/g), hypertension, obesity (BMI 34). Current diabetes regimen: Glargine 30 units QHS, glipizide 10 mg BID, metformin 1000 mg BID. Patient experiencing hypoglycemic episodes 1-2x/week.

❓ Question: What medication changes would optimize this patient's regimen?

✅ Answer: Add SGLT2i, discontinue glipizide, reduce metformin or stop (due to eGFR), reduce glargine dose

📖 Explanation:

Problems Identified:

1. ❌ Hypoglycemia risk: Glipizide (sulfonylurea) + insulin = high hypo risk
2. ❌ Metformin dosing: eGFR 38 → should limit to 1000 mg daily max or discontinue (varies by guideline; FDA says avoid <30, some say <45)
3. ❌ No organ-protective therapy: Missing SGLT2i despite CKD with albuminuria (PRIME indication!)
4. ❌ Suboptimal A1C despite polypharmacy

Optimized Regimen:

• ADD: Dapagliflozin 10 mg daily or empagliflozin 10 mg daily

  • CREDENCE/DAPA-CKD data: Profound renal protection at this eGFR
  • Slows progression to ESKD
  • Will improve A1C ~0.5-0.7%

• DISCONTINUE: Glipizide

  • Causing hypoglycemia
  • Renally cleared (worse with CKD)
  • No CV/renal benefit

• ADJUST: Metformin

  • Reduce to 500-1000 mg daily OR discontinue if institutional protocol requires stopping <45 eGFR
  • Lactic acidosis risk (though debated)

• REDUCE: Glargine

  • Start with 20% reduction (30 → 24 units)
  • SGLT2i will lower glucose—prevent hypo by reducing basal insulin
  • Continue to titrate based on fasting glucose

Expected Outcomes:

• ↓ Hypoglycemia episodes (remove sulfonylurea, reduce insulin)
• ↓ A1C to ~7.5-7.8% (SGLT2i effect)
• Renal protection: Slower eGFR decline, ↓ albuminuria
• ↓ CV event risk
• Weight loss 2-3 kg

⚠️ Monitoring: Check eGFR 2-4 weeks after starting SGLT2i (expect 5-10% dip—continue therapy), monitor fasting glucose daily initially to adjust insulin, recheck A1C in 3 months.

---

Example 4: Combination Therapy Strategy

Case: 54-year-old female with T2DM (newly diagnosed A1C 9.8%), obesity (BMI 38), hypertension, no known CVD. Motivated to avoid insulin, concerned about weight gain. eGFR >90, no albuminuria, lipids at goal on statin.

❓ Question: Design an optimal initial regimen focusing on weight loss and CV risk reduction.

✅ Answer: Metformin + GLP-1 RA + SGLT2i triple combination

📖 Explanation:

This patient is ideal for maximal non-insulin therapy given:

• High A1C (9.8%) needing substantial reduction
• Obesity (weight loss critical)
• Multiple CV risk factors (obesity, HTN, diabetes)
• Desire to avoid insulin

Rationale for Each Agent:

1. Metformin 1000 mg BID (titrate from 500 mg)

   • First-line per all guidelines
   • A1C reduction ~1-1.5%
   • Weight neutral
   • Inexpensive

2. GLP-1 RA (semaglutide 2.4 mg weekly preferred)

   • A1C reduction ~1.5-2%
   • Weight loss 10-15% (especially high-dose semaglutide)
   • CV benefit (SUSTAIN-6)
   • Addresses obesity + CV risk

3. SGLT2i (empagliflozin 10 mg or dapagliflozin 10 mg)

   • A1C reduction ~0.7-1%
   • Weight loss 2-4%
   • CV/renal protection (primary prevention)
   • Complementary mechanism to GLP-1 RA

Combined Expected Effects:

• A1C reduction: 3-4% total → expect final A1C ~5.8-6.8% ✅
• Weight loss: 12-18% (significant improvement) ✅
• CV protection: Both agents reduce future CV events ✅
• Hypoglycemia risk: None (all glucose-dependent) ✅

💊 Initiation Strategy:

• Week 0: Start metformin 500 mg daily with dinner
• Week 1: Increase metformin to 500 mg BID
• Week 2: Add SGLT2i (empagliflozin 10 mg AM)
• Week 3: Increase metformin to 1000 mg BID
• Week 4: Add GLP-1 RA (semaglutide 0.25 mg SC weekly)
• Week 8: Increase semaglutide to 0.5 mg weekly
• Week 12: Increase to 1 mg weekly
• Continue titrating semaglutide monthly up to 2.4 mg weekly based on tolerance

Patient Counseling:

• GLP-1 RA: Expect nausea first 2-4 weeks (improves), inject weekly same day
• SGLT2i: Increased urination, genital hygiene important, stay hydrated
• Metformin: Take with food, may cause GI upset initially
• No hypoglycemia expected with this regimen
• Expect significant weight loss over 6-12 months

💡 NAPLEX Pearl: Combining GLP-1 RA + SGLT2i is safe, effective, and increasingly common for patients needing substantial A1C reduction with weight loss. They work through complementary mechanisms with no pharmacokinetic interactions.

---

Common Mistakes to Avoid ⚠️

❌ Mistake 1: Discontinuing SGLT2i Due to Initial eGFR Dip

Why it's wrong: The acute 5-10% eGFR decrease in first 2-4 weeks is hemodynamic (afferent arteriole vasoconstriction) and protective, not nephrotoxic. This is the mechanism of long-term kidney protection!

✅ Correct approach: Continue therapy unless >30% decline, AKI suspected, or volume depletion present. The eGFR stabilizes then declines slower than placebo over time.

---

❌ Mistake 2: Avoiding SGLT2i in Patients Without Diabetes

Why it's wrong: SGLT2i benefits for HF and CKD are independent of diabetes status. DAPA-HF, EMPEROR trials included non-diabetics with same benefit.

✅ Correct approach: Recommend SGLT2i for ALL patients with HFrEF (EF ≤40%) or CKD with albuminuria, regardless of diabetes diagnosis. This is guideline-directed therapy!

---

❌ Mistake 3: Using GLP-1 RA Without Adequate Nausea Counseling

Why it's wrong: Nausea (20-40%) is the #1 reason for discontinuation. Patients unaware it's transient may stop therapy prematurely.

✅ Correct approach:

• Set expectations: "Nausea is common in first 2-4 weeks but usually improves"
• Start lowest dose, titrate slowly (every 4 weeks minimum)
• Provide anti-nausea strategies (small meals, avoid high-fat foods)
• Consider anti-emetics short-term if severe
• Reassure that GI effects typically resolve

---

❌ Mistake 4: Not Reducing Insulin/Sulfonylurea When Adding SGLT2i or GLP-1 RA

Why it's wrong: While neither causes hypoglycemia alone, they lower glucose significantly. If patient is on insulin or sulfonylurea, hypo risk increases unless doses adjusted.

✅ Correct approach:

• Reduce basal insulin by 10-20% when adding GLP-1 RA or SGLT2i
• Reduce/discontinue sulfonylurea (or reduce insulin significantly)
• Monitor glucose closely first 2 weeks
• Titrate insulin/sulfonylurea based on glucose readings

---

❌ Mistake 5: Missing DKA Risk Counseling with SGLT2i

Why it's wrong: Euglycemic DKA is rare but serious. Patients (especially T1DM or insulin-requiring T2DM) need to know triggers and when to stop therapy.

✅ Correct approach: Counsel ALL patients on SGLT2i:

• Stop medication 3 days before surgery
• Stop during acute illness with poor PO intake
• Seek care for unexplained nausea, vomiting, abdominal pain, fatigue (even if glucose normal)
• Never drastically reduce insulin or carbs without medical supervision

---

❌ Mistake 6: Choosing Canagliflozin for Patient with PAD or Fracture History

Why it's wrong: CANVAS trial showed increased amputation (primarily toes) and fracture risk specifically with canagliflozin.

✅ Correct approach: For patients with PAD, neuropathy, amputation history, or osteoporosis, choose empagliflozin or dapagliflozin instead. Perform foot exams regularly if canagliflozin used.

---

❌ Mistake 7: Using Same GLP-1 RA Dose for All Patients

Why it's wrong: Titration is REQUIRED for tolerability. Starting at maintenance dose causes severe nausea and early discontinuation.

✅ Correct approach:

• Always start at lowest dose (e.g., semaglutide 0.25 mg, dulaglutide 0.75 mg)
• Increase dose every 4 weeks minimum
• Some patients tolerate lower doses long-term—that's okay! (Still get benefits)
• For weight loss specifically, higher doses needed (semaglutide 2.4 mg)

---

Key Takeaways 🎯

---

📚 Further Study

1. ADA Standards of Care 2024 - Cardiovascular Disease and Risk Management Section
   https://diabetesjournals.org/care/issue/47/Supplement_1

2. ACC/AHA/HFSA Heart Failure Guidelines - SGLT2i as Guideline-Directed Medical Therapy
   https://www.ahajournals.org/doi/10.1161/CIR.0000000000000757

3. KDIGO Clinical Practice Guideline for Diabetes Management in CKD - SGLT2i and GLP-1 RA Recommendations
   https://kdigo.org/guidelines/diabetes-ckd/

---

🎓 Congratulations! You've mastered the cardiovascular and renal benefits of GLP-1 RAs and SGLT2 inhibitors—knowledge that will serve you on NAPLEX and in clinical practice. Remember: these aren't just "diabetes drugs" anymore; they're organ-protective therapies that save lives and prevent disease progression. Always think beyond A1C! 💪